登录新浪财经APP 搜索【信披】查看更多考评等级 证券日报网讯 1月5日,天士力在互动平台回答投资者提问时表示,根据公司《2025年半年度报告》,PD-L1/VEGF双抗的实体瘤适应症IIa期、直肠癌适应症IIb期临床试验正在入组中;培重组人成纤维细胞生长因子21注射液,临床试验已进入Ib期。后续研发进展公司会根据信息披露相关规定进行公告。(文章来源:证券日报) 海量资讯、精准解读,尽在新浪...
Source Link登录新浪财经APP 搜索【信披】查看更多考评等级 证券日报网讯 1月5日,天士力在互动平台回答投资者提问时表示,根据公司《2025年半年度报告》,PD-L1/VEGF双抗的实体瘤适应症IIa期、直肠癌适应症IIb期临床试验正在入组中;培重组人成纤维细胞生长因子21注射液,临床试验已进入Ib期。后续研发进展公司会根据信息披露相关规定进行公告。(文章来源:证券日报) 海量资讯、精准解读,尽在新浪...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.